Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in com...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Faggiano, A, Ramundo, V, Dicitore, A, Castiglioni, S, Borghi, M O, Severino, R, Ferolla, P, Crinò, L, Abbruzzese, A, Sperlongano, P, Caraglia, M, Ferone, D, Hofland, L, Colao, A, Vitale, G
Format: Artigo
Sprache:Inglês
Veröffentlicht: Blackwell Publishing Ltd 2012
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3823224/
https://ncbi.nlm.nih.gov/pubmed/21883896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2011.01438.x
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge